The November 4, 2013, announcement by the Department of Justice that J&J will pay more than $2 Billion to settle civil and criminal claims against
GlaxoSmithKline Plc (GSK)’s anti-seizure drug Potiga now carries a black-box warning in the U.S. on risks including potential vision loss.
The warning, the most serious type the U.S. Food and Drug Administration issues, underscores risks of abnormalities in the eye, vision loss and skin discoloration,
